
In the REDES study, shorter asthma duration was associated with better lung function in severe asthma patients treated with mepolizumab for 12 months. Patients with less disease persistence showed higher FEV1 values and a greater proportion with ≥80% pre-BD FEV1.
Like
Save
Share